Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Current Assets (2016 - 2025)

Historic Current Assets for RedHill Biopharma (RDHL) over the last 14 years, with Q2 2025 value amounting to $12.6 million.

  • RedHill Biopharma's Current Assets fell 2004.71% to $12.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $12.6 million, marking a year-over-year decrease of 2004.71%. This contributed to the annual value of $11.9 million for FY2024, which is 2620.2% down from last year.
  • As of Q2 2025, RedHill Biopharma's Current Assets stood at $12.6 million, which was down 2004.71% from $11.9 million recorded in Q4 2024.
  • RedHill Biopharma's Current Assets' 5-year high stood at $98.5 million during Q2 2021, with a 5-year trough of $11.9 million in Q4 2024.
  • In the last 5 years, RedHill Biopharma's Current Assets had a median value of $27.0 million in 2023 and averaged $49.8 million.
  • As far as peak fluctuations go, RedHill Biopharma's Current Assets soared by 6112.62% in 2021, and later plummeted by 8121.07% in 2023.
  • Over the past 5 years, RedHill Biopharma's Current Assets (Quarter) stood at $89.2 million in 2021, then dropped by 3.65% to $85.9 million in 2022, then plummeted by 81.21% to $16.1 million in 2023, then fell by 26.2% to $11.9 million in 2024, then grew by 5.41% to $12.6 million in 2025.
  • Its last three reported values are $12.6 million in Q2 2025, $11.9 million for Q4 2024, and $15.7 million during Q2 2024.